Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 20/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.60 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.60 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3987613 | 0.94 | PIK3CB (0.70) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4784099 | 0.87 | PIK3CB (0.72) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4780048 | 0.86 | PIK3CB (0.67) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4838764 | 0.86 | PIK3CB (0.58) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4728818 | 0.84 | PIK3CB (0.60) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL13606677 | 0.83 | PIK3CB (0.81) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL947722 | 0.83 | PIK3CB (0.69) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4515272 | 0.81 | PIK3CB (0.65) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4537235 | 0.81 | PIK3CB (0.62) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4532249 | 0.81 | PIK3CB (0.62) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008032027-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |